At Regeneron, we have always been driven by the belief that bold science leads to big breakthroughs. For nearly four decades, we have been at the forefront of scientific and technological innovation, pushing the boundaries of what is possible and redefining the way medicine is discovered, developed, and delivered. Today, we stand as a premier biotechnology company with a proven track record of converting scientific discoveries into life-changing medicines. With 14 approved medicines in the United States (“U.S.”) or other countries, including four current blockbuster therapies, our work has touched the lives of millions around the globe, helping them live fuller, healthier lives. Yet, as we survey our broad and robust clinical and scientific pipeline, we know the best is yet to come. We remain committed as ever to turning our science into real-world impact, delivering long-term growth for the company and lasting value for patients, society, and our shareholders. To do that, we cannot stand still. In a rapidly evolving industry, we are constantly challenging ourselves to raise the bar. Whether it is developing new standards of care or facing biosimilar competition, we view every challenge as an opportunity to refocus, reinvent, and ultimately bring best-in-class innovations to patients.